

## Evaluation of Medications for HFpEF:


Class	Benefit	Initiating and Monitoring	Clinical Pearls
Blood Pressure Management	<ul style="list-style-type: none"> <li>- Medications should be titrated to attain clinical practice guidelines to prevent morbidity</li> </ul>	<ul style="list-style-type: none"> <li>- Monitor for decrease in BP and HR</li> <li>- Assess symptoms and titrate per hypertension guidelines</li> </ul>	<ul style="list-style-type: none"> <li>- Optimal BP goal and antihypertensive regimens are not known for patients with HFpEF</li> <li>- RASS antagonists may be first line given data in HFpEF trials</li> <li>- Consider other comorbidities and potential benefits of one BP medication over another</li> </ul>
SGLT2	<ul style="list-style-type: none"> <li>- Beneficial for decreasing HF hospitalization and cardiovascular mortality</li> <li>- Effects seen regardless of diabetic diagnosis</li> <li>- NYHA Class II-IV</li> </ul>	<ul style="list-style-type: none"> <li>- Monitor for Scr, BUN, Na+</li> <li>- Assess signs of yeast or urine infection</li> <li>- No titration</li> </ul>	<ul style="list-style-type: none"> <li>- All home SGLT2i will be interchanged to empagliflozin</li> <li>- Empagliflozin can be used with eGFR <math>\geq</math> 25 and renal function is stable or improving</li> <li>- Caution for patients with recurrent UTIs</li> </ul>
ARNi	<ul style="list-style-type: none"> <li>- More beneficial for the low end of the LVEF spectrum</li> <li>- Might help reduce HF related hospitalizations</li> </ul>	<ul style="list-style-type: none"> <li>- Monitor for drop in BP and increase in SCr, BUN, K+</li> <li>- Assess symptoms and titrate per hypertension guidelines</li> </ul>	<ul style="list-style-type: none"> <li>- If switching from an ACEi, allow 36-hour washout period before starting the ARNi</li> <li>- No washout for switching from an ARB</li> </ul>
MRA	<ul style="list-style-type: none"> <li>- More beneficial for the low end of the LVEF spectrum</li> <li>- Might help reduce HF related hospitalizations</li> </ul>	<ul style="list-style-type: none"> <li>- Monitor BP and check SCr, BUN, K+</li> <li>- Assess symptoms</li> <li>- No titration</li> </ul>	<ul style="list-style-type: none"> <li>- Caution with diuretic dosing at initiation to minimize risk of hyperkalemia and worsening renal function</li> </ul>
ARB	<ul style="list-style-type: none"> <li>- More beneficial for the low end of the LVEF spectrum</li> <li>- Might help reduce HF related hospitalizations</li> </ul>	<ul style="list-style-type: none"> <li>- Monitor for drop in BP and increase in SCr, BUN, K+</li> <li>- Assess symptoms and titrate per hypertension guidelines</li> </ul>	<ul style="list-style-type: none"> <li>- May provide additional benefits for hypertension and albuminuria</li> </ul>
Fluid Control	<ul style="list-style-type: none"> <li>- Diuretics should be used for symptom relief due to edema and volume overload</li> </ul>	<ul style="list-style-type: none"> <li>- Loop diuretics are preferred</li> <li>- Monitor fluid status, K+, Mg, and renal function</li> </ul>	<ul style="list-style-type: none"> <li>- May add a thiazide or metolazone if patients have refractory edema unresponsive to loop diuretics alone</li> </ul>

\*HF = heart failure;; BP = blood pressure; HR = heart rate; NYHA = New York Heart Association; SCr = serum creatinine; BUN = blood urea nitrogen; K+ = serum potassium; Mg = serum magnesium; LVEF = left ventricular ejection fraction; eGFR = estimated glomerular filtration rate; ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker

### Medications to avoid and recommend discontinuation of:

- Non-steroidal anti-inflammatory drugs (NSAIDs): aspirin, meloxicam, sulindac, ibuprofen, naproxen, ketorolac, celecoxib
- Cold and cough medications with pseudoephedrine and phenylephrine
- Alka-seltzer
- Thiazolidinediones (TZDs): pioglitazone
- Non-dihydropyridine calcium channel blockers (Non-DHP CCBs): cardizem and verapamil
- Always question herbals and natural supplements

## Treatment of HFpEF



### References:

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063